SEC Comment Letter 0000000000-24-005970 to Organon & Co. (OGN) (CIK 0001821825) (OGN)
Organon & Co. (OGN) (CIK 0001821825)
Date: May 23, 2024 · CIK: 0001821825 · Accession: 0000000000-24-005970
AI Filing Summary & Sentiment
File numbers found in text: 001-40235
Letter
United States securities and exchange commission logo May 23, 2024 Matthew Walsh Chief Financial Officer Organon & Co. 30 Hudson Street, Floor 33 Jersey City, New Jersey 07302 Re:Organon & Co. Form 10-K for Fiscal Year Ended December 31, 2023 Form 8-K filed May 2, 2024 Response dated May 14, 2024 File No. 001-40235 Dear Matthew Walsh: We have reviewed your May 14, 2024 response to our comment letter and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our April 30, 2024 letter.
FirstName LastNameMatthew Walsh Comapany NameOrganon & Co. May 23, 2024 Page 2 FirstName LastName Matthew Walsh Organon & Co. May 23, 2024 Page 2 Form 8-K filed May 2, 2024 Exhibits 1.We note your response to prior comment 2 and the updated presentation included within Table 4 of Exhibit 99.1 from the Form 8-K dated May 2, 2024. However, the updated presentation continues to include most of the line items and subtotals found in your GAAP income statement and adds a measure of gross profit not found in your Form 10-Q. As previously requested, please remove this presentation from future filings or alternatively explain to us in detail how this presentation complies with the guidance in Question 102.10(a) and (c) of the C&DIs for Non-GAAP Financial Measures. Please contact Gary Newberry at 202-551-3761 or Tara Harkins at 202-551-3639 if you have questions regarding comments on the financial statements and related matters. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 23, 2024
Matthew Walsh
Chief Financial Officer
Organon & Co.
30 Hudson Street, Floor 33
Jersey City, New Jersey 07302
Re:Organon & Co.
Form 10-K for Fiscal Year Ended December 31, 2023
Form 8-K filed May 2, 2024
Response dated May 14, 2024
File No. 001-40235
Dear Matthew Walsh:
We have reviewed your May 14, 2024 response to our comment letter and have the
following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments. Unless
we note otherwise, any references to prior comments are to comments in our April 30,
2024 letter.
FirstName LastNameMatthew Walsh
Comapany NameOrganon & Co.
May 23, 2024 Page 2
FirstName LastName
Matthew Walsh
Organon & Co.
May 23, 2024
Page 2
Form 8-K filed May 2, 2024
Exhibits
1.We note your response to prior comment 2 and the updated presentation included within
Table 4 of Exhibit 99.1 from the Form 8-K dated May 2, 2024. However, the updated
presentation continues to include most of the line items and subtotals found in your GAAP
income statement and adds a measure of gross profit not found in your Form 10-Q. As
previously requested, please remove this presentation from future filings or alternatively
explain to us in detail how this presentation complies with the guidance in Question
102.10(a) and (c) of the C&DIs for Non-GAAP Financial Measures.
Please contact Gary Newberry at 202-551-3761 or Tara Harkins at 202-551-3639 if you
have questions regarding comments on the financial statements and related matters.
Sincerely,
Division of Corporation Finance
Office of Life Sciences